Accès ouvert
2025
article
OpenAlex
Lauren J. Kelsey, Nicole Seiberlich, Ashok Srinivasan, Mohannad M. Ibrahim et autres
RATIONALE AND OBJECTIVES: The purpose of this study is to evaluate whether the whole-body 0.55 T MRI may be a clinically acceptable or non-inferior alternative to 1.5T/3T for internal auditory canal (IAC) imaging due to greater field homogeneity and resultant reduced susceptibility …
us
(code pays fourni par la source)
2025
conference-paper
OpenAlex
Lauren J. Kelsey, Ashok Srinivasan, Eric A. Liao, Mohannad M. Ibrahim et autres
Motivation: Identify whether 0.55T MRI may be superior or a clinically acceptable alternative to 1.5T/3T for temporal bone evaluation Goal(s): To compare image quality, visibility of temporal bone anatomy, and cochlear measurements at 0.55T vs. 1.5T/3T, using high-resolution CT (HRCT) as the …
Accès ouvert
2025
article
OpenAlex
Obaidah Bitar, Aparna Joshi, Tresa Griffith, Sarah Clos et autres
OBJECTIVES: To evaluate the perception of clinical faculty and staff on the discontinuation of routine gonadal shielding for diagnostic imaging procedures and assess the impact of targeted educational intervention on awareness and comfort levels. METHODS: A pre-post survey study was conducted among …
us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Laura Beatriz Prato, A. Rezzag Lebza, Amandine Consumi, Marine Tessier et autres
Background: Traumatic brain injury (TBI) is a major cause of disabilities in industrialized countries. Cognitive decline typically occurs in the chronic phase of the condition, following cellular and molecular processes. In this study, we described the use of KCC2, a neuronal-specific potassium-chloride …
fr, in, fi
(code pays fourni par la source)
2025
article
OpenAlex
Anna Lavrova, Shruti Mishra, John Kim, Remy R. Lobo et autres
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Swati Naik, Ying Li, Aimee C. Talleur, Subodh Selukar et autres
BACKGROUND: Relapse remains a challenge after transplantation in pediatric patients with hematological malignancies. Myeloablative regimens used for disease control are associated with acute and long-term adverse effects. We used a CD45RA-depleted haploidentical graft for adoptive transfer of memory T cells combined with …
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Amr Qudeimat, Shruthi Suryaprakash, Renee M. Madden, Ashok Srinivasan et autres
Not available.
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Rebecca Epperly, Ying Li, Subodh Selukar, Emily Y. Zeng et autres
Patients with hematologic malignancies who relapse after allogeneic hematopoietic cell transplantation (HCT) have a poor prognosis. Although proceeding to subsequent HCT can provide potential for long-term survival, there are limited data to guide which patients are most likely to benefit and which …
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Shruthi Suryaprakash, Yilun Sun, Li Tang, Dinesh Keerthi et autres
Donor lymphocyte infusion (DLI) is a form of adoptive immunotherapy administered in patients experiencing mixed chimerism (MC) or disease relapse after an allogeneic hematopoietic cell transplantation (HCT). Success is limited by the occurrence of acute and chronic graft-versus-host disease (GVHD). To determine …
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Shruthi Suryaprakash, Yu Bi, Subodh Selukar, Dinesh Keerthi et autres
Acute megakaryocytic leukemia (AMKL) comprises 4-15% of all acute myeloid leukemia (AML) diagnoses in pediatric patients. Unlike patients with Down syndrome who have a >80% expected survival, the 5-year overall survival (OS) in patients with de novo AMKL ranges between 14-49%. While …
us
(code pays fourni par la source)
Accès ouvert
2023
conference-abstract
OpenAlex
Shruthi Suryaprakash, Yu Bi, Subodh Selukar, Dinesh Keerthi et autres
Introduction Acute megakaryocytic leukemia (AMKL) comprises 4-15% of all acute myeloid leukemia (AML) diagnoses in pediatric patients. Unlike patients with Down syndrome who have a >80% expected survival with dose-reduced chemotherapy, the 5-year overall survival (OS) in patients with de novo AMKL …
us
(code pays fourni par la source)
2023
conference-abstract
OpenAlex
Shruthi Suryaprakash, Yilun Sun, Li Tang, Dinesh Keerthi et autres
Introduction: Donor lymphocyte infusion (DLI) is a form of adoptive immunotherapy administered to enhance the graft-versus-leukemia (GVL) effect after an allogeneic hematopoietic cell transplantation (HCT). DLI is frequently chosen for its ease of administration and low risk of graft ablation as compared …
us
(code pays fourni par la source)